Search

The efficacy of taktivin was examined by comparison of the time-course of changes in cellular immunity, the course of the underlying disease and the incidence of infectious complications in two groups of patients with systemic lupus erythematosus (SLE). The first group included 49 patients aged 8 to 15 years receiving taktivin, the second one 34 children of the same age not given immunomodulatory therapy. The morphofunctional status of the thymus was studied in 9 cases on autopsy. The prolonged treatment with taktivin (for 4 weeks and over) resulted in an increase of the number of patients with the improved health status and reduction of SLE activity, in a rise of the content of serum thymic factor, activation of the processes of T lymphocyte differentiation, in an increase of the lymphocyte count in patients with secondary infection, activation of phagocytosis, rise of bactericidal activity of the serum, which entailed the elimination and prevention of the development of secondary infectious complications. Taktivin promotes the normalization of the thymic structure and exerts a replacement effect.

The authors analyze the course of acute virus hepatitis B in 11 children. Provide results of the treatment with T-activin of K cells in vitro and the clinico-immunologic data on 26 patients afflicted with lingering hepatitis B before and after the treatment with T-activin. Show the hereditary predisposition to an unfavourable course of virus hepatitis B.

The authors analyze the results of the treatment of 366 children afflicted with lymphogranulomatosis. All the patients received treatment from 1976 to 1990 according to three combined programs. The necessity is demonstrated of the individual treatment with regard to the predictors. Immunocorrection by means of taktivin was employed in patients with immunity disorders. The perfection of a complex of treatment measures favoured an increase of the survival to over 5 years in 93.8% of cases.